Home > Journals > Medicine > European Journal of Dermatology > summary
 
      Advanced search    Shopping cart    French version 
 
Latest books
Catalogue/Search
Collections
All journals
Medicine
European Journal of Dermatology
- Current issue
- Archives
- Subscribe
- Order an issue
- More information
Biology and research
Public health
Agronomy and biotech.
My account
Forgotten password?
Online account   activation
Subscribe
Licences IP
- Instructions for use
- Estimate request form
- Licence agreement
Order an issue
Pay-per-view articles
Newsletters
How can I publish?
Journals
Books
Help for advertisers
Foreign rights
Book sales agents



 

Texte intégral de l'article
 
Printable version

Interferon‐gamma in alopecia areata


European Journal of Dermatology. Volume 14, Number 1, 33-6, January-February 2004, Investigative report

Free Article  

Author(s) : Ercan ARCA, Ugur MUSABAK, Ahmet AKAR, A. Hakan ERBIL, H. Blent TATAN

Summary : Alopecia areata is a common type of hair loss. In clinical practice most patients will present with reversible patchy hair loss whereas others may develop complete baldness. Although the etiopathogenesis of alopecia areata is poorly understood, evidence is accumulating that it can be regarded as a T‐cell mediated tissue‐restricted autoimmune disease of the hair follicle, especially expressing the T‐helper‐type 1 cytokines interleukin‐1β, interleukin‐2, and interferon‐γ. The aim of the study was to compare the serum levels of interferon‐γ in patients with alopecia areata and the control group and also to investigate the difference between the localized form of the disease with the extensive forms like alopecia totalis (AT) and alopecia universalis (AU). Forty patients with alopecia areata and 20 healthy controls were enrolled in the study. Nineteen patients had localized AA (LAA) and twenty‐one patients had AT, AU or AT\\AU. The serum levels of interferon‐γ were measured using enzyme immunoassay techniques. The mean serum IFN‐γ level in AA patients (n ∓ 40) was 14.25 ± 8.76 pg\\mL (mean ± SD), whereas that of LAA (n ∓ 19) or extensive (AT, AU or AT\\AU) (n ∓ 21) was 13.45 ± 6.75 pg\\mL or 14.98 ± 10.37 pg\\mL, respectively. The mean serum IFN‐γ level in controls was 9.95 ± 2.6 pg\\mL. Serum levels of IFN‐γ in patients with AA were significantly higher than those in controls (p <\; 0.05). Significant difference was observed in serum levels of IFN‐γ between patients with LAA and control group (p <\; 0.05). Serum levels of IFN‐γ in patients with AT, AU or AT\\AU were significantly higher than those in controls (p <\; 0.05). There was no significant difference in levels of IFN‐γ between patients with LAA and extensive group (p > 0. 05). We conclude that the elevated serum levels of IFN‐γ may reflect the inflammatory symptoms in AA, especially in the extensive form and that control of IFN‐γ production may be important to management of this disease. And also the measurement of serum IFN‐γ in patients with AA may be useful in discriminating those likely to progress to AU from the remaining LAA, or as a prognostic indicator.

Keywords : Alopecia areata, interferon‐gamma

 

About us - Contact us - Conditions of use - Secure payment
Latest news - Conferences
Copyright © 2007 John Libbey Eurotext - All rights reserved
[ Legal information - Powered by Dolomède ]